FDA approval of sugammadex sodium for intravenous use; this is a regulatory action, not a clinical efficacy study, and does not report trial outcomes or comparative benefit.
Reported
Approval date2026-07-28
Formulation 1 strength500 mg base/5 mL (100 mg base/mL)
Formulation 2 strength200 mg base/2 mL (100 mg base/mL)